We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+48.19%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$439M
AUM Growth
-$62.6M
Cap. Flow
-$159M
Cap. Flow %
-36.16%
Top 10 Hldgs %
66.42%
Holding
69
New
13
Increased
8
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$37.3M
2
MDT icon
Medtronic
MDT
+$17.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$12M
4
PFE icon
Pfizer
PFE
+$9.04M
5
KVUE icon
Kenvue
KVUE
+$5.41M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$20.4M
2
THC icon
Tenet Healthcare
THC
+$18.7M
3
DXCM icon
DexCom
DXCM
+$18.4M
4
HNGE
Hinge Health
HNGE
+$16.7M
5
BSX icon
Boston Scientific
BSX
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.02%
2 Consumer Staples 0.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KVUE icon
26
Kenvue
KVUE
$37.4B
$4.3M 0.98%
+265,200
New +$5.41M
IMUX icon
27
Immunic
IMUX
$192M
$4.14M 0.94%
469,941
-91,640
-16% -$808K
ARQT icon
28
Arcutis Biotherapeutics
ARQT
$3.53B
$4.04M 0.92%
214,400
-53,600
-20% -$845K
EXAS
29
DELISTED
Exact Sciences
EXAS
$4.03M 0.92%
73,600
-281,400
-79% -$14.1M
PHAT icon
30
Phathom Pharmaceuticals
PHAT
$958M
$3.6M 0.82%
306,000
-758,500
-71% -$7.83M
RGEN icon
31
Repligen
RGEN
$7.37B
$3.11M 0.71%
23,300
-83,200
-78% -$10.1M
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$4.4B
$3.07M 0.7%
+144,000
New +$3.41M
ASND icon
33
Ascendis Pharma A/S
ASND
$16.7B
$2.88M 0.66%
+14,500
New +$2.7M
ELVN icon
34
Enliven Therapeutics
ELVN
$3.77B
$2.87M 0.65%
140,300
+129,000
+1,142% +$2.6M
BEAM icon
35
Beam Therapeutics
BEAM
$2.64B
$2.72M 0.62%
112,000
-297,400
-73% -$5.92M
SCYX icon
36
SCYNEXIS
SCYX
$36.1M
$2.58M 0.59%
418,816
+265,202
+173% +$1.8M
HQY icon
37
HealthEquity
HQY
$8.24B
$2.4M 0.55%
25,300
-66,700
-73% -$6.28M
WVE icon
38
Wave Life Sciences
WVE
$1.15B
$2.18M 0.5%
+297,500
New +$2.41M
XENE icon
39
Xenon Pharmaceuticals
XENE
$6.38B
$2.14M 0.49%
53,400
-54,491
-51% -$1.92M
AKRO
40
DELISTED
Akero Therapeutics
AKRO
$1.92M 0.44%
40,500
-93,500
-70% -$4.53M
INSM icon
41
Insmed
INSM
$22.9B
$1.67M 0.38%
11,600
-47,400
-80% -$5.81M
KPTI icon
42
Karyopharm Therapeutics
KPTI
$162M
$880K 0.2%
134,566
– –
IMRX icon
43
Immuneering
IMRX
$285M
$636K 0.14%
+90,900
New +$472K
ALT icon
44
Altimmune
ALT
$583M
– –
-105,000
Closed -$406K
APGE icon
45
Apogee Therapeutics
APGE
$10.2B
– –
-65,000
Closed -$2.82M
AXSM icon
46
Axsome Therapeutics
AXSM
$12.4B
– –
-94,500
Closed -$9.86M
BBIO icon
47
BridgeBio Pharma
BBIO
$16.6B
– –
-140,000
Closed -$6.05M
CAH icon
48
Cardinal Health
CAH
$53.7B
– –
-15,000
Closed -$2.52M
DOCS icon
49
Doximity
DOCS
$3.78B
– –
-60,000
Closed -$3.68M
DXCM icon
50
DexCom
DXCM
$28.3B
– –
-210,500
Closed -$18.4M
1
2
3

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2025 Portfolio in Review

As of Q3 2025, Avidity Partners Management held 69 positions worth $439M, down 12% from $502M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avidity Partners Management withdrew a net $159M in Q3 2025, closing 26 positions and reducing 20 holdings. Its most notable exit was Tenet Healthcare, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Consumer Staples.

Against the trend, Avidity Partners Management opened a new position in Medtronic worth $18.2M.

  • Avidity Partners Management's largest Q3 2025 buy was Medtronic: 190,600 shares worth $18.2M.
  • Avidity Partners Management added most to Dianthus Therapeutics in Q3 2025, an estimated $37.3M increase.
  • Avidity Partners Management's biggest Q3 2025 reduction was Natera, cutting an estimated $20.4M.
  • Avidity Partners Management fully exited Tenet Healthcare in Q3 2025, selling an estimated $18.7M.
  • Avidity Partners Management's ten largest holdings make up 66% of its $439M portfolio in Q3 2025.
  • Avidity Partners Management opened 13 new positions and closed 26 in Q3 2025.
  • Avidity Partners Management's portfolio value fell 12% quarter-over-quarter to $439M.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.